KRAS+ Non-Small Cell Lung Cancer

ALK+ NSCLC
KRYSTAL Data on Adagrasib Plus Pembrolizumab in KRAS-Mutated NSCLC Presented at ELCC 2025
Marina Garassino, MD, presented results from the phase 2 portion of the trial at the European Lung Cancer Congress.
Advertisement

Expert Interviews

Advertisement
Advertisement
Latest News

April 16, 2025